Last reviewed · How we verify
KYMRIAH
At a glance
| Generic name | KYMRIAH |
|---|---|
| Also known as | tisagenlecleucel |
| Sponsor | Masonic Cancer Center, University of Minnesota |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (PHASE2)
- Long-term Follow up Local Registry Study of Kymriah in South Korea
- Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies (PHASE1)
- Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (PHASE2)
- MT2017-45: CAR-T Cell Therapy for Heme Malignancies (PHASE2)
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KYMRIAH CI brief — competitive landscape report
- KYMRIAH updates RSS · CI watch RSS
- Masonic Cancer Center, University of Minnesota portfolio CI